{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "PRE", "messageBoardId": "finmb_41955650", "regularMarketChangePercent": 1.9323653, "regularMarketPrice": 6.33, "exchange": "NGM", "shortName": "Ocular Therapeutix, Inc.", "longName": "Ocular Therapeutix, Inc.", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1406295000000, "priceHint": 2, "regularMarketChange": 0.119999886, "regularMarketTime": 1684180805, "regularMarketDayHigh": 6.465, "regularMarketDayRange": "6.21 - 6.465", "regularMarketDayLow": 6.21, "regularMarketVolume": 868615, "regularMarketPreviousClose": 6.21, "bid": 0.0, "ask": 0.0, "bidSize": 13, "askSize": 10, "fullExchangeName": "NasdaqGM", "financialCurrency": "USD", "regularMarketOpen": 6.25, "averageDailyVolume3Month": 1021446, "averageDailyVolume10Day": 987100, "fiftyTwoWeekLowChange": 3.76, "fiftyTwoWeekLowChangePercent": 1.4630351, "fiftyTwoWeekRange": "2.57 - 6.865", "fiftyTwoWeekHighChange": -0.53499985, "fiftyTwoWeekHighChangePercent": -0.077931516, "fiftyTwoWeekLow": 2.57, "fiftyTwoWeekHigh": 6.865, "earningsTimestamp": 1683577800, "earningsTimestampStart": 1691405940, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.14, "epsForward": -0.94, "epsCurrentYear": -1.15, "priceEpsCurrentYear": -5.504348, "sharesOutstanding": 77516600, "bookValue": 0.125, "fiftyDayAverage": 5.5677, "fiftyDayAverageChange": 0.7623, "fiftyDayAverageChangePercent": 0.13691472, "twoHundredDayAverage": 4.5883, "twoHundredDayAverageChange": 1.7416997, "twoHundredDayAverageChangePercent": 0.37959585, "marketCap": 512804672, "forwardPE": -6.7340426, "priceToBook": 50.64, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "Ocular Therapeutix", "symbol": "OCUL"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "24 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "fax": "781 357 4001", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 274, "companyOfficers": [{"maxAge": 1, "name": "Mr. Antony  Mattessich", "age": 54, "title": "Pres, CEO & Director", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 1049350, "fmt": "1.05M", "longFmt": "1,049,350"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Donald  Notman Jr.", "title": "Chief Financial Officer", "fiscalYear": 2022, "totalPay": {"raw": 630872, "fmt": "630.87k", "longFmt": "630,872"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Rabia Gurses Ozden M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 621386, "fmt": "621.39k", "longFmt": "621,386"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Peter K. Jarrett Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1957, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Philip C. Strassburger Esq.", "age": 62, "title": "Gen. Counsel", "yearBorn": 1960, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. William H. Ransone II", "title": "VP of Global Sales & Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Tracy  Smith", "title": "VP of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher G. White", "age": 60, "title": "Chief Bus. Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Karen-Leigh  Edwards M.B.A., Ph.D.", "title": "Sr. VP of Technical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Steve  Meyers", "title": "Sr. VP of Commercial", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}